Eyepoint Pharmaceuticals (EYPT)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from EYPT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Eyepoint Pharmaceuticals's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $37M | $41M | $46M | $43M | $31M |
| Net income | -$58M | -$102M | -$71M | -$131M | -$232M |
| Free cash flow | -$50M | -$67M | -$2M | -$130M | -$243M |
| EPS (diluted) | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
| Operating margin | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own EYPT
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Eyepoint Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 16, 2026 | Jay S Duker |
1,500 | $13.15 | $19,725 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when EYPT trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Eyepoint Pharmaceuticals insiders buying the stock?
1 open-market insider purchase of EYPT in the last 12 months, from SEC Form 4 filings.
Companies like Eyepoint Pharmaceuticals
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.